Wedbush Initiates Coverage On TScan Therapeutics with Outperform Rating, Announces Price Target of $8
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst David Nierengarten initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with an Outperform rating and announces a price target of $8.
June 22, 2023 | 8:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten initiates coverage on TScan Therapeutics with an Outperform rating and a price target of $8.
The initiation of coverage by Wedbush with an Outperform rating and a price target of $8 indicates a positive outlook for TScan Therapeutics. This news is likely to have a positive short-term impact on TCRX's stock price as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100